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        Celiac disease (CD) is an infl  ammatory enter-
opathy induced by gluten-derived prolamines 
in genetically susceptible individuals. CD aff  ects 
about 1 in 100 individuals in Europe and the 
United States (  1, 2  ). The associated intestinal in-
fl  ammation results from synergism between in-
nate and adaptive immune responses to gliadin 
peptides. The adaptive immune response is or-
chestrated by CD4  +   T cells recognizing various 
deamidated gliadin peptides (  3  ), including a 
33-mer (peptide 56-88 [p56-88]) (  4  ), bound to 
HLA-DQ2/8 molecules (  5  ). p56-88 is a power-
ful immunodominant gliadin peptide extremely 
resistant to gastrointestinal digestion and has far 
higher T cell stimulatory potency than its 12-mer 
counterparts (  6  ). The innate immune response in 
CD is triggered by a distinct set of gliadin pep-
tides: one prototype innate peptide is p31-49, 
common to the N terminus of A-gliadins and 
shown to be toxic for CD patients both in vitro 
and in vivo ( 7  –  9  ). This peptide was recently shown 
to stimulate the synthesis of IL-15 (  10, 11  ), a 
proinfl  ammatory cytokine that can promote the 
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  Celiac disease (CD) is an enteropathy resulting from an abnormal immune response to 
gluten-derived peptides in genetically susceptible individuals. This immune response is 
initiated by intestinal transport of intact peptide 31-49 (p31-49) and 33-mer gliadin 
peptides through an unknown mechanism. We show that the transferrin receptor CD71 is 
responsible for apical to basal retrotranscytosis of gliadin peptides, a process during which 
p31-49 and 33-mer peptides are protected from degradation. In patients with active CD, 
CD71 is overexpressed in the intestinal epithelium and colocalizes with immunoglobulin (Ig) 
A. Intestinal transport of intact p31-49 and 33-mer peptides was blocked by polymeric 
and secretory IgA (SIgA) and by soluble CD71 receptors, pointing to a role of SIgA  –  gliadin 
complexes in this abnormal intestinal transport. This retrotranscytosis of SIgA  –  gliadin 
complexes may promote the entry of harmful gliadin peptides into the intestinal mucosa, 
thereby triggering an immune response and perpetuating intestinal infl  ammation. Our 
fi  ndings strongly implicate CD71 in the pathogenesis of CD. 144 TRANSCYTOSIS OF I  G  A  –  GLIADIN PEPTIDE COMPLEXES | Matysiak-Budnik
  Consistent with a possible role of gliadin-specifi  c IgA in 
the luminal uptake of gliadin peptides in active CD, immuno-
fl   uorescence studies of duodenal biopsies revealed large 
amounts of IgA at the apical pole of the surface epithelium 
in patients with active CD, whereas in control subjects and 
treated CD patients, IgA was restricted to the crypts and was 
not observed in villous epithelium (  Fig. 1 B   and Fig. S1, avail-
able at http://www.jem.org/cgi/content/full/jem.20071204/
DC1). In patients with active CD, colocalization of IgA with 
cytokeratin or alkaline phosphatase (a brush-border enzyme) 
confi  rmed the presence of IgA at the apex of surface epithelial 
cells (  Fig. 1 C  ). 
  CD71 is overexpressed in the apical pole of enterocytes 
in active CD 
  IgA involvement in the intestinal transport of gliadin peptides 
would imply the presence of IgA receptors on the apical pole 
of enterocytes. In addition to the pIg receptor (pIgR; also 
called membrane secretory component [SC]), which permits 
transcytosis of dimeric IgA (dIgA) from the lamina propria 
and its delivery into the intestinal lumen, complexed to the 
cleaved extracellular part of pIgR (bound SC) in the form of 
SIgA, enterocytes express a second receptor able to bind IgA, 
namely CD71 (  19, 24  ). In normal intestinal epithelium, CD71 
mediates the rapid endocytosis/recycling of Tf necessary to 
deliver iron to rapidly proliferating epithelial cells (  25  ). The 
level of CD71 expression is also linked to body iron stores 
and correlates negatively with the serum iron concentration. 
CD71 can be up-regulated in CD patients with iron defi  -
ciency anemia (  26  ). The recent demonstration that CD71 
can bind IgA1 at the surface of mesangial cells in IgA nephro-
pathy (  19  ), together with a previous report indicating up-
regulation of intestinal CD71 by IL-15 in CD (  27  ), led us 
to investigate whether CD71 mediates abnormal IgA retro-
transport in CD. 
  The distribution of CD71 in active CD was assessed in 
duodenal biopsies by both immunoperoxidase and immuno-
fl  uorescence detection (  Fig. 2, A and B  ).   In control biopsies, 
CD71 expression was confi  ned to the basolateral pole of vil-
lous epithelial cells and was observed at both the basal and 
apical poles of crypt epithelial cells. In contrast, in active CD, 
CD71 was strongly expressed all over the epithelial layer, in-
cluding the fl  at surface epithelium. Staining was not restricted 
to the basolateral compartment but was also detected at the 
apical pole of epithelial cells in a subapical rather than strictly 
apical location, possibly corresponding to the apical recycling 
compartment from which this receptor is rapidly recycled 
to the cell surface (  28  ). A similar abnormal distribution of 
CD71 expression was observed in patients with refractory celiac 
sprue who have a fl  attened overproliferating mucosa. In con-
trast, CD71 expression was normal in treated CD patients who 
had recovered a normal or subnormal epithelial architecture. 
The strong expression of CD71 contrasted with the lack of 
signifi  cant expression of CD89, the myeloid IgA Fc receptor 
(  29  ), on either enterocytes or immune cells in the lamina 
propria of controls and CD patients (unpublished data) (  30  ). 
CD4  +   adaptive immune response (  11  ) and activate cytotoxic 
activity and IFN-     production in intraepithelial lympho-
cytes (  12  –  14  ). 
  This activation of the local immune system implies that 
undigested gliadin fragments present in the intestinal lumen 
somehow cross the intestinal epithelium. Indeed, apical to 
basal transport and processing of gliadin peptides, particularly 
of p31-49 and 33-mer, are severely altered in active CD, lead-
ing to the release of intact peptides on the basal side, whereas 
the same peptides are almost entirely degraded during their 
intestinal transport in control individuals and treated CD pa-
tients (  15, 16  ). Several lines of evidence argue against simple 
nonspecifi  c paracellular leakage of gliadin peptides across the 
celiac mucosa. In particular, a 12-mer gliadin peptide, p57-68, 
is completely degraded during intestinal transport in patients 
with active CD, suggesting no paracellular leakage of mole-
cules of this size or larger. In addition, only 0.3% of the apical 
peptide crosses the epithelium during a 3-h incubation period, 
arguing against free diff  usion across a damaged mucosa. The 
  “  protected  ”   transport of p31-49 thus involves a transcellular 
pathway (  15, 16  ), which enables the peptide to escape lyso-
somal degradation. As active CD is associated with high con-
centrations of antigliadin IgA antibodies in the intestinal lumen 
(  17, 18  ), we postulated that the transport of intact gliadin pep-
tides might result from abnormal retrotranscytosis of IgA  –  gliadin 
complexes. Indeed, although antigliadin IgA antibodies are 
a hallmark of CD, they have no known pathogenic role. We 
obtained evidence that polymeric/secretory IgA (pIgA/SIgA) 
can mediate protected transport of p31-49 and 33-mer gliadin 
peptides through their binding to CD71, the transferrin (Tf) 
receptor. Importantly, we found that this receptor was abnor-
mally expressed at the apical pole of enterocytes in patients with 
active CD. Although initially implicated in endocytosis of 
iron-loaded Tf, CD71 was recently recognized as an IgA re-
ceptor mediating mesangial deposition of IgA1 complexes in 
IgA nephropathy (  19  ). 
    RESULTS   
  High molecular weight immune complexes containing 
gliadin-specifi  c IgA and transglutaminase (Tgase) 
are present in patients with active CD 
  Active CD is associated with enhanced intestinal secretory im-
munity (  17, 20  ) and with higher antigliadin antibody titers in 
serum and jejunal secretions than in controls and treated CD 
patients (  17, 20, 21  ). In addition, gliadin colocalizes with Tgase 
(the autoantigen in CD) in the epithelium and subepithelium 
of patients with active CD (  22  ). We postulated that, as in IgA 
nephropathy, high molecular weight immune complexes (  23  ) 
might be present in CD patients. As shown in   Fig. 1 A  , antigli-
adin IgA antibodies and Tgase were detected within high mo-
lecular weight immune complexes, which were found in larger 
amounts in the serum and duodenal secretions of patients with 
active CD than in those of treated CD patients and controls.   
The presence of Tgase in these immune complexes may be re-
lated to the cross-linking capacity of this enzyme, contributing 
to the formation of IgA  –  gliadin  –  Tgase complexes. JEM VOL. 205, January 21, 2008 
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sies from patients with active CD but not from treated CD 
patients or controls. The presence of CD71 at the brush-border 
membrane of enterocytes in patients with active CD and its 
colocalization with IgA was confi  rmed by immunogold electron 
microscopy (  Fig. 2 D   and Fig. S2, available at http://www
.jem.org/cgi/content/full/jem.20071204/DC1). 
  As SIgA is the main IgA subtype present in the intestinal 
lumen, we examined whether it can bind CD71. The capacity 
of pIgA and SIgA to bind to Daudi cells, which express CD71 
as the only IgA receptor (  19  ), was studied by fl  ow cytometry. 
Both pIgA and SIgA were able to bind Daudi cells, and this 
Collectively, these results were compatible with a role of CD71 
in IgA binding at the apical surface of enterocytes in active CD. 
  IgA colocalizes with CD71 and p31-49 at the apical pole 
of enterocytes in active CD 
  The possible role of apically expressed CD71 in the binding 
of IgA  –  gliadin peptide complexes in patients with active CD 
was fi  rst addressed by performing colocalization immunofl  u-
orescence studies on frozen sections. Colocalization (white) of 
IgA (green) and CD71 (blue) was observed at the apical pole 
(and the basal pole) of epithelial cells (  Fig. 2 C  ) in fresh biop-
    Figure 1.         IgA and IgA  –  gliadin complexes are overexpressed in CD.   (A) Analysis of IgA immune complexes (IC) isolated from the serum and duode-
nal secretions of patients with active or treated CD and controls. PEG precipitates containing high molecular weight IC were analyzed by ELISA. Plates 
were coated with Frazer  ’  s fraction (pepsin/trypsin gliadin hydrolysate) or anti-Tgase antibody, followed by anti  –  human IgA–horseradish peroxidase. 
Results are presented as OD values obtained with all sera or duodenal secretions tested. A signifi  cant increase in IC recognizing gliadin peptides and con-
taining Tgase was observed in the active CD group compared with the treated CD and control groups in both serum and duodenal secretion. Horizontal 
lines represent medians. *, P   <   0.0005 and 0.01 compared with the control and treated CD groups, respectively; #, P   <   0.01 and 0.02 compared with the 
control and treated CD groups, respectively. (B) IgA is concentrated at the apical pole of surface enterocytes in active CD. Cryosections of duodenal 
mucosa from control subjects, patients with active or treated CD, and patients with refractory celiac sprue were labeled with anti-IgA  –  FITC antibody and 
TOPRO-3 (blue nuclei). In controls, treated CD patients, and patients with refractory celiac sprue, IgA staining of epithelial cells was located at the basal 
pole of villous cells and at the apical and basal poles of crypt cells. In contrast, in patients with active CD, IgA staining was concentrated at the apical pole 
of the surface epithelium (and of crypt cells; Fig. S1). Results are representative of three controls, seven patients with treated CD, and six patients with 
active CD. (C) IgA overexpression observed at the apical pole of epithelial cells of patients with active CD was located inside the cell, including the brush 
border membrane, as shown by its colocalization with cytokeratin and alkaline phosphatase, a marker of apical membranes. No such colocalization was 
seen in controls. Bars, 50   μ  m.     146 TRANSCYTOSIS OF I  G  A  –  GLIADIN PEPTIDE COMPLEXES | Matysiak-Budnik
ization with p31-49 in treated patients was compatible with 
total degradation of the peptide during intestinal transport 
(  Fig. 3 A  ).   The red fl  uorescence observed in the lamina propria 
of treated CD patients (and, to a lesser extent, in patients with 
active CD) is likely related to the release of the TAMRA fl  u-
orescent label after endocytosis and hydrolysis of p31-49 by 
epithelial cells. Collectively, these results support the hypothesis 
that CD71 may bind SIgA  –  gliadin peptide complexes at the 
apical surface in active CD. 
binding was inhibited by prior incubation of IgA with soluble 
CD71 receptors (  Fig. 2 E  ), acting as a competitive inhibitor. 
  Finally, colocalization of IgA (green) and p31-49  –  tetra-
methyl-6-carboxyrhodamine (TAMRA; red) was studied after 
applying the peptide for 15 min at 37  °  C on the apical side of 
biopsies mounted in Ussing chambers. As shown in   Fig. 2 F  , 
colocalization of p31-49 and IgA was detected in biopsies from 
patients with active CD but not in those from treated CD 
patients (or controls; not depicted). The lack of IgA colocal-
    Figure 2.         CD71 expression and colocalization with IgA and p31-49 in duodenal biopsies.   (A) Expression of CD71 (immunoperoxidase labeling) on 
duodenal biopsies from controls, patients with active or treated CD, and patients with refractory celiac sprue. Compared with controls, CD71 was over-
expressed in patients with active CD and in patients with refractory celiac sprue. At higher magnifi  cation (bottom), strong CD71 expression was observed 
all over the surface epithelium in patients with active CD, whereas in controls and treated CD patients CD71 expression was only observed at the basal pole 
of villous epithelial cells and in crypt cells. (B) CD71 overexpression by surface epithelium of patients with active CD was confi  rmed by immunofl  uorescent 
labeling. The fl  uorophore was a cy5-conjugated secondary antibody (blue staining). Results in A and B are representative of three control subjects, four 
treated CD patients, eight patients with active CD, and two patients with refractory celiac sprue. (C) Double immunofl  uorescence labeling of IgA  –  CD71 in 
duodenal biopsies. Colocalization (white) of IgA (green) and CD71 (blue) was observed at the apical surface of the epithelium in active CD (  n   = 5), but not 
in controls or in treated CD patients (  n   = 3). (D) Immunogold electron microscopy with double labeling of IgA (10-nm particles; arrowhead) and CD71 
(15-nm particles; arrow). In active CD, IgA and CD71 were expressed in the brush border membrane and subepithelial compartments, and IgA  –  CD71 co-
localization was frequent (boxes). No such colocalization was observed in controls (see additional images of one control subject and two patients with 
active CD in Fig. S2). (E) SIgA can bind CD71 at the cell surface of a B cell line (Daudi cells) known to express CD71 as the only IgA receptor. Cells were 
incubated for 30 min at 4  °  C with 500   μ  g/ml SIgA or pIgA1 in the presence or absence of 500   μ  g/ml of soluble CD71. IgA was revealed with biotinylated 
anti-IgA and allophycocyanin-labeled streptavidin (green line). Both pIgA1 and SIgA specifi  cally bound CD71, as the binding was inhibited by soluble CD71 
receptors (pink line). The black line indicates the isotope control. (F) Colocalization (yellow) of IgA (green) and p31-49 (red) in duodenal biopsies from two 
patients with active CD, mounted in Ussing chambers and exposed to p31-49  –  TAMRA on the apical side for 15 min at 37  °  C before being fi  xed, cryosec-
tioned, and stained with anti-IgA  –  FITC antibodies. No colocalization was found in two treated CD patients or in a control (not depicted). Bars, 50   μ  m.     JEM VOL. 205, January 21, 2008 
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  3  H-labeled p31-49 was transported intact across the duodenal 
mucosa of patients with active CD who have both a fl  at mucosa 
and IgA lining the surface epithelium (  Fig. 3 A  ). In contrast, this 
peptide was almost totally degraded during transport through 
samples from control subjects and treated CD patients who had 
a normal intestinal epithelium with much less CD71 and IgA 
than patients with active CD. Furthermore, the peptide was 
similarly degraded during transport across duodenal biopsies 
  IgA mediates intestinal transport of intact p31-49 
through CD71 
  To directly address the role of IgA in the protected apical to 
basal transport of gliadin peptides, duodenal biopsies were 
mounted in Ussing chambers and   3  H-labeled p31-49 was ap-
plied to the apical side. Intestinal transport was evaluated by 
analyzing   3  H-labeled fragments in the basal compartment 3 h 
later. Confi  rming our published results (  15  ), a large fraction of 
    Figure 3.         IgA involvement in intestinal transport and processing of   3  H-labeled p31-49.   (A) Transport and processing of p31-49 showing typical 
RP-HPLC elution pattern of   3  H-labeled material in the basal compartment of duodenal biopsies incubated for 3 h after apical addition of   3 H-labeled 
p31-49. In controls and treated CD patients, p31-49 was almost completely degraded during transport, as   >  95% of the total radioactivity was eluted as free 
  3  H-labeled proline in the basal compartment. In contrast, in patients with active CD (  n   = 7), a large fraction of p31-49 was found on the basal side of the 
intestinal mucosa, mainly in intact form or as active fragments. Interestingly, in three patients with refractory celiac sprue (fl  at mucosa and an absence of 
antigliadin IgA), near-complete degradation of the peptide was observed after intestinal transport, suggesting that a fl  at mucosa is not responsible for 
the transport of intact peptide observed in patients with active CD. (B) Mean percentage of tritiated intact p31-49, active fragments, and proline found in 
the basal compartment after intestinal transport of p31-49 by duodenal biopsies from controls, patients with treated CD, and patients with active CD. The 
percentage of intact p31-49 plus active fragments crossing the duodenal biopsies (mean   ±   SD) was signifi  cantly higher in active CD (57   ±   18%;   n   = 17) 
than in treated CD (23   ±   23%;   n   = 8) and controls (26   ±   4%;   n   = 4). *, P   <   0.007. (C) Inhibitory effect of pIgA, SIgA, and mIgA on the transport of intact 
p31-49. To test the involvement of IgA in the transport of intact p31-49, we performed competitive inhibition experiments with different forms of IgA. In 
a typical RP-HPLC elution profi  le of   3  H-labeled p31-49 obtained in biopsies from the patient with active CD shown in A, 85% of p31-49 was transported 
intact in basal conditions, whereas this percentage fell sharply in the presence of pIgA and SIgA but not mIgA (mIgA does not bind signifi  cantly to CD71; 
reference   31  ). (D) Intestinal transport of p31-49 in patients with active CD showing the percentage of intact p31-49 plus active fragments found in the 
basal compartment of Ussing chambers after blockade with mIgA, dIgA, pIgA, or SIgA. Compared with   “  peptide alone  ”   (median = 50;   n   = 7), dIgA (median 
= 23;   n   = 3), pIgA (median = 0;   n   = 3), and SIgA (median = 0;   n   = 5), but not mIgA (median = 60;   n   = 3), signifi  cantly inhibited the intestinal transport of 
p31-49. *, P   <   0.01 compared with peptide alone. (E) Effect of IgG and Tf on the transport of intact p31-49. 50   μ  g/ml IgG and 10   μ  g/ml Tf were preincu-
bated for 30 min on the apical side of duodenal biopsies mounted in Ussing chambers before adding   3  H-labeled p31-49. The basal compartment was 
collected after 3 h and analyzed by radio RP-HPLC to detect p31-49 and its metabolites. No inhibitory effect on p31-49 transport was observed.     148 TRANSCYTOSIS OF I  G  A  –  GLIADIN PEPTIDE COMPLEXES | Matysiak-Budnik
IgG and human Tf were unable to inhibit the protected trans-
port pathway (  Fig. 3 E  ), indicating that gliadin-specifi  c IgG does 
not play a major role in the intestinal absorption of gliadin 
peptides in patients with active CD. The failure of Tf to inhibit 
p31-49 transport is in line with its inability to inhibit IgA bind-
ing to CD71 on Daudi cells (  31  ) and suggests that IgA and Tf 
do not share the same binding site on CD71. In addition, the 
anti-CD71 mAb A24 did not inhibit the transport of intact 
p31-49 in active CD, suggesting that A24, like Tf, does not 
bind CD71 at the same site as IgA (Fig. S3 A, available at 
http://www.jem.org/cgi/content/full/jem.20071204/DC1) 
(  32  ). Also, an mAb directed to SC was not able to block the 
transport of IgA  –  p31-49 complexes (Fig. S3 B). Finally, we used 
a mAb to Tgase II (anti  –  Tgase II, 6B9) or dansyl cadaverin, an 
inhibitor of Tgase activity, to test the involvement of Tgase II, 
and no inhibitory eff  ect was observed. 
  To confi  rm the role of CD71 in the transport of intact p31-
49, we tested the capacity of a soluble CD71 receptor to com-
petitively inhibit this transport in duodenal biopsies from six 
from three patients with refractory celiac sprue, a complicated 
form of CD associated with severe villous atrophy, CD71 api-
cal overexpression but no detectable IgA on the epithelial cell 
surface (  Fig. 1 B   and   Fig. 3 A  ). The latter result indicates that 
nonspecifi  c leakage caused by epithelial fl  attening is not suffi   -
cient to explain the increased transport of the intact peptide 
observed in active CD. The percentage of intact p31-49 and 
active fragments found in the basal compartment in active CD 
is signifi  cantly higher than that observed in controls and treated 
CD patients (  Fig. 3 B  ). Adding an excess of dIgA, pIgA, or 
SIgA to the apical compartment of duodenal biopsies from 
patients with active CD, as competitive inhibitors of endoge-
nous gliadin-specifi  c IgA, strongly inhibited the transport of 
intact p31-49 (  Fig. 3, C and D  ), indicating that large IgA mol-
ecules are involved in this transport. In contrast, monomeric 
IgA (mIgA) had no inhibitory eff  ect, as expected in view of its 
low affi   nity for CD71 (  31  ). 
  To better understand the mechanism underlying intestinal 
transport of p31-49, we tested potentially inhibitory molecules. 
    Figure 4.         Inhibitory effect of soluble CD71 on the transport of intact p31-49.   (A) Typical HPLC elution profi  les of p31-49 after intestinal transport 
across duodenal biopsies from patients with active CD.   3  H-labeled radioactive material is present in the basal compartment of the duodenal biopsies in Ussing 
chambers 3 h after adding   3  H-labeled p31-49 to the apical compartment. In basal conditions, intact p31-49 or active fragments were present in the basal 
compartment. Soluble CD71 (sCD71) reduced the transport of intact p31-49, whereas soluble CD89 (sCD89) had no effect. (B) Inhibition of intestinal 
transport of   3  H-labeled p31-49 in the presence of sCD71. The histogram shows the mean percentage of intact p31-49 and its active fragments found in the 
basal compartment after intestinal transport. Compared with peptide alone (median = 50;   n   = 6), signifi  cant inhibition was observed in the presence of 
30   μ  g/ml sCD71 (median= 21;   n   = 6) but not sCD89 (median = 46;   n   = 4). The horizontal lines indicate median values, and dotted lines join paired results 
from the same patient. *, P   <   0.01 compared with peptide alone.     JEM VOL. 205, January 21, 2008 
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dIgA, pIgA, and soluble CD71 (  Fig. 5 B  , right). The percentage 
of 33-mer crossing the intestinal mucosa in intact form was 
signifi  cantly reduced by dIgA and pIgA (7 and 14%, respec-
tively) and by soluble CD71 (19%) compared with the peptide 
alone (46%; P   <   0.01), further supporting CD71 mediation 
of protected IgA  –  33-mer complex retrotransport. 
    DISCUSSION   
  This study reveals that protected transport of gliadin peptides 
in CD is driven by retrotranscytosis of SIgA through the Tf 
receptor (CD71), which is abnormally expressed on the apical 
side of the intestinal epithelium. This process may sustain anti-
gliadin immune responses and aggravate intestinal infl  amma-
tion in CD patients. 
  Ig-mediated transport of luminal antigens across the epithe-
lium has already been reported in various situations. Protected 
apical to basal intestinal transport of IgE  –  allergen complexes 
patients with active CD using Ussing chambers. When soluble 
CD71 receptor was added to the apical compartment, reversed-
phase HPLC (RP-HPLC) analysis of the radioactive material 
recovered in the basal compartment after intestinal transport of 
  3  H-labeled p31-49 showed that transport of the intact peptide 
was signifi  cantly inhibited (  Fig. 4, A and B  ).   In contrast, soluble 
CD89 receptor had no inhibitory eff  ect, in accordance with 
the absence of CD89 expression in epithelial cells. 
  IgA mediates the intestinal transport of intact 33-mer 
via CD71 
  Intestinal transport of 33-mer in the form of the intact peptide 
and large immunogenic 12-mer (  16  ) fragments (35 and 28%, 
respectively) was signifi  cantly higher in active CD than in con-
trols (4 and 9%) and in treated CD (12 and 8%) (  Fig. 5, A and B  , 
left), confi  rming our previous results (  15, 16  ).   In active CD, 
competitive inhibition of 33-mer transport was attempted with 
    Figure 5.         Duodenal transport of 33-mer in patients with active CD, and competitive inhibition by IgA and soluble CD71.   (A) Typical RP-HPLC 
elution profi  le of   3  H-labeled 33-mer after intestinal transport across duodenal biopsies from a control individual and a patient with active CD, mounted in 
Ussing chambers.   3  H-labeled radioactive material present in the basal compartment 3 h after adding   3  H-labeled 33-mer to the apical compartment is 
shown. The percentages of the different eluted fractions (proline, small and large fragments, and intact 33-mer) were quantifi  ed with Radiostar software. 
The control tissue almost totally degraded the 33-mer peptide, whereas digestion was incomplete in the sample from the patient with active CD. (B, left) 
Mean percentages of 33-mer and its fragments after intestinal transport. The duodenal mucosa of patients with active CD does not completely degrade 
33-mer, as 38 and 22% of intact peptide and large fragments, respectively, were recovered in the basal compartment, compared with 4 and 9% in control 
subjects. Treated CD patients had an intermediate profi  le (12 and 8%). (right) dIgA, pIgA, and soluble CD71 (sCD71) signifi  cantly inhibited the transport of 
intact 33-mer but not of large fragments. *, P   <   0.04 compared with control; #, P   <   0.04 compared with peptide alone.     150 TRANSCYTOSIS OF I  G  A  –  GLIADIN PEPTIDE COMPLEXES | Matysiak-Budnik
anemia are all associated with substantial CD71 up-regulation 
all over the surface epithelium, and this may be responsible for 
its missorting toward the apical pole of enterocytes. This is 
compatible with a role of CD71 in the endo  cytosis of IgA com-
plexes from the apical cell surface. Previous studies have shown 
in nonpolarized cells that pIgA binding to CD71 induces the 
internalization and rapid addressing of IgA-loaded CD71 into 
recycling vesicles (  31  ). The colocalization that we observed be-
tween IgA and CD71 and between IgA and p31-49 in active 
CD but not in controls suggests that IgA  –  gliadin complexes 
might bind CD71. These fi  ndings, combined with the demon-
stration that soluble CD71 receptors (as well as dIgA, pIgA, and 
SIgA) can block the protected transcellular transport of intact 
p31-49 and 33-mer, provide strong evidence that CD71 is the 
receptor that allows gliadin peptides bound to SIgA to translo-
cate from the intestinal lumen into the lamina propria in active 
CD. Interestingly, the capacity of CD71 to mediate pIgA bind-
ing to mesangial cells of patients with IgA nephropathy also un-
derlines the pathogenic role of CD71  –  IgA interactions in IgA 
nephropathy (  19, 31  ). The presence of glomerular IgA deposits 
in a signifi  cant proportion of newly diagnosed CD patients (  47  ) 
and the abnormally elevated incidence of CD in patients with 
IgA nephropathy (  48  ) provides a link between these diseases. 
  The specifi  c retrotranscytosis of SIgA  –  gliadin complexes in 
CD may appear puzzling given the presence of SIgA with di-
verse specifi  cities in the intestinal lumen. First, large IgA com-
plexes bind CD71 with higher affi   nity than smaller IgA species 
such as SIgA (  31  ). Second, SIgA  –  gliadin complexes could be 
selectively retrotranscytosed with the help of tissue Tgase, which 
we detected in the high molecular weight IgA immune com-
plexes found in duodenal secretions. Indeed, Tgase can cross-
link gliadin peptides and promote receptor-mediated endocytosis 
(  49  ), particularly the internalization step of CD71 (  50  ), and was 
recently detected at the surface of enterocytes in active CD (  51  ). 
However, neither Tgase antibodies nor an inhibitor of Tgase 
activity could inhibit the protected transport pathway in biopsy 
specimens from patients with active CD, suggesting that Tgase 
is not directly involved in the transport process or that Tgase 
  eff  ect is irreversible in biopsies from patients with active CD 
mounted in Ussing chambers. Finally, the pIgA and SIgA con-
centrations used in our Ussing chamber experiments were high 
enough, in view of the small exposed surface area (0.025 cm  2  ), 
for competitive inhibition of IgA  –  gliadin transport to occur. 
  Gliadin-specifi  c SIgA is present at high titers in the intestinal 
lumen of patients with active CD but is also found in healthy 
individuals (  52, 53  ). In contrast, apical to basal delivery of intact 
gliadin peptides is only observed in active CD. Our data indi-
cate that CD71 overexpression and misaddressing to the apical 
pole of enterocytes is a key event in the intestinal retrotransport 
of SIgA  –  gliadin complexes (  Fig. 6  ).   They also indicate that the 
normal function of SIgA, namely the containment of harmful 
antigens in the intestinal lumen, is defi  cient in CD. This could 
account for the abnormal immune response to gluten in geneti-
cally susceptible (HLA-DQ2/8) individuals. 
  It is unclear whether this abnormal transport is the trigger-
ing event in CD or whether it becomes operational secondarily, 
through CD23, the low-affi   nity IgE receptor, has been shown 
in allergic patients and might elicit rapid activation of intestinal 
mast cells ( 33  –  35  ). Comparable protected transport of IgG –  anti-
gen complexes via the neonatal Fc receptor has also been dem-
onstrated. This receptor, initially described at the apical surface 
of enterocytes in newborn rodents (  36  ) and human fetal in-
testine (  37, 38  ), could transport IgG into the intestinal lumen 
and recycle IgG  –  antigen complexes back into the lamina pro-
pria, thereby promoting a specifi  c immune response (  38  ). 
  In this study, we tested the hypothesis that, in active CD, 
SIgA-gliadin immune complex retrotransport could be medi-
ated by CD71 and, thus, explain the protected transport of gli-
adin peptides in celiac patients. In healthy individuals, vectorial 
intestinal transport of IgA consists mainly of basal to apical 
transcytosis of dIgA via the pIgR, leading to the release of SIgA 
in the intestinal lumen (  39  ), where it retains microbial and 
food antigens and confers protective mucosal immunity. Al-
though basal to apical transfer of IgA is the norm in epithelia, 
apical to basal retrotransport of SIgA through M cells overlying 
Peyer  ’  s patches has been documented in mice (  40, 41  ) even 
though specifi  c IgA receptors are not identifi  ed. Several lines 
of evidence support retrotransport of SIgA-gliadin complexes 
in active CD. First, the intestinal lumen of patients with active 
CD contains elevated levels of antigliadin IgA antibodies (  17  ), 
which can bind a set of gliadin peptides (  42, 43  ) including the 
33-mer (  44  ) and p31-55 (  45  ). We show the presence of high 
molecular weight gliadin-specifi  c IgA immune complexes con-
taining Tgase. This is an important fi  nding, as IgA in form of 
high molecular weight complexes binds CD71 with high af-
fi  nity (  31  ). Second, we show that IgA is more strongly con-
centrated at the apical pole of surface epithelial cells in active 
CD than in treated CD patients, refractory celiac patients, and 
control subjects, and that this pattern correlates with substantial 
transport of intact p31-49 and 33-mer in active CD, whereas 
this transport is negligible in controls, treated CD patients, and 
patients with refractory celiac sprue. Finally, IgA involvement 
in the protected transport of these gliadin peptides is indicated 
by the competitive inhibition of their transport by pIgA ob-
served in this study. Although inhibition of 33-mer transport 
by IgA concerns the intact peptide only and not its large 12-mer 
fragments, these latter fragments have been shown to stimulate 
T cells much less potently than the intact peptide (  6  ). One pos-
sible explanation is partial resistance of 33-mer to lysosomal 
degradation during fl  uid-phase transcytosis occurring in parallel 
with receptor-mediated transcytosis. 
  A role of IgA in protected transcytosis of gliadin peptides 
would imply the presence of a receptor able to bind pIgA/SIgA 
at the apical surface of enterocytes. Our fi  ndings highlight the 
role of the Tf receptor CD71, a newly identifi  ed IgA receptor. 
Previous studies have shown that CD71 binds pIgA but not 
mIgA (  31  ). In this study, we show that CD71 can also bind 
SIgA, the main form of IgA present in the intestinal lumen. In 
the normal intestine, CD71 is mainly expressed in crypts (re-
stricted to the basolateral membrane of epithelial cells) (  46  ) with 
little expression in the villous epithelium. In active CD, villous 
fl  attening, increased epithelial renewal, and iron-defi  ciency JEM VOL. 205, January 21, 2008 
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this protected transport pathway might provide a new thera-
peutic option, blocking the cascade that perpetuates innate 
and adaptive immune responses to gluten in patients with 
active CD. 
  MATERIALS AND METHODS 
  Patients 
  We studied 26 patients with active CD, 13 treated CD patients who had 
been on a gluten-free diet for at least 1 yr, 4 patients with refractory celiac 
sprue, and 10 nonceliac control subjects. Diagnosis of active CD was based 
on subtotal or total villous atrophy and positivity for antigliadin, anti-Tgase, 
and antiendomysium IgA antibodies. Refractory celiac sprue was defi  ned as 
CD resistant to a gluten-free diet, characterized by the persistence of villous 
atrophy in the absence of antigliadin IgA antibodies. The control subjects 
underwent upper endoscopy for routine diagnostic purposes (e.g., dyspepsia 
and chronic diarrhea) and had a normal intestinal mucosa. All the patients 
underwent duodenal endoscopy, during which four to six additional biopsy 
samples were taken from the distal duodenum for research purposes. In some 
cases, duodenal secretions were obtained by infusion  –  aspiration of 50 ml of 
phosphate-buff  ered saline. Local ethics committee (Comit  é   de Protection 
des Personnes Ile de France II) approval was obtained, and all of the patients 
signed an informed consent to participate in the study. 
  Purifi  cation of IgA and synthesis of soluble IgA receptors 
  Competing IgA used in the Ussing chamber studies was human myeloma 
IgA1 protein prepared according to Chevailler et al. (  56  ). mIgA, dIgA, and 
pIgA were separated by gel fi  ltration on columns (  >  98% pure; Sephacryl 
S300 [GE Healthcare]) (  57  ). SIgA consisting of pooled human colostrum 
was obtained from Fitzgerald or Biotrend. The soluble IgA receptors sCD71 
(TfR) and sCD89 were used. Both soluble receptors were expressed in a 
lytic baculovirus/insect cell expression system, as described previously (  19  ). 
perpetuating infl  ammation once the mucosa has fl  attened. 
Several environmental factors may serve as initial triggers for 
SIgA  –  gliadin complex entry into intestinal tissue. Among 
these factors, iron defi  ciency anemia, by inducing CD71 up-
regulation, could promote the delivery of the SIgA  –  gliadin 
complex, triggering abnormal intestinal responses in suscep-
tible individuals. In addition, strong intestinal epithelial cell 
proliferation secondary to epithelial damage by intestinal in-
fection might also stimulate CD71 overexpression and thereby 
favor the onset of CD in susceptible individuals. It is note-
worthy that frequent rotavirus infection is associated with a 
higher risk of autoimmunity, defi  ned as positivity for tissue 
Tgase, in early childhood (  54  ). 
  Finally, if CD71 is necessary for CD to develop, why do 
patients with treated CD react so rapidly to the ingestion of 
gluten in the absence of CD71 expression? Some CD patients 
on a gluten-free diet still have minor small bowel abnormal-
ities, and there is evidence that the celiac epithelium may be 
persistently activated even after successful treatment and mu-
cosal healing (  55  ). It is possible that residual expression of CD71 
at the apical membrane of enterocytes may drive the entry of 
small amounts of gliadin peptides that are nonetheless suffi   -
cient to reactivate gluten-sensitive memory T cells and par-
ticipate in rapid relapse. 
  In conclusion, we describe a novel mechanism of CD71-
mediated IgA transcytosis that enables gliadin peptides to enter 
the lamina propria of patients with active CD. Inhibition of 
    Figure 6.         Overview of postulated Tf receptor (CD71)  –  mediated transport of IgA  –  gliadin complexes in CD.   In healthy individuals, gliadin pep-
tides (resistant to luminal degradation) are taken up nonspecifi  cally by enterocytes and are degraded by lysosomal acid proteases during fl  uid-phase 
transcytosis. Very few toxic peptides are delivered into the intestinal lamina propria. In patients with active CD, abnormal expression of CD71 (Tf receptor) 
at the apical pole of enterocytes allows receptor-mediated uptake of SIgA  –  gliadin peptide complexes and their protected transport toward the lamina 
propria and, thus, toward the local immune system. The exact part of the SIgA molecule involved in CD71 binding is not known. Blockade of gliadin pep-
tide entry into the intestinal mucosa might serve as the basis for a novel therapeutic strategy in CD.     152 TRANSCYTOSIS OF I  G  A  –  GLIADIN PEPTIDE COMPLEXES | Matysiak-Budnik
  All immunolabeling experiments included negative controls in which 
the primary antibody was replaced by concentration-matched isotype controls 
(Becton Dickinson). The isotype control used for the anti-IgA  –  FITC primary 
conjugate was a goat IgG  –  FITC (Abcam). In some experiments, nuclei were 
labeled with TOPRO-3 (blue fl  uorescence; Invitrogen). Slides were read 
with a laser scanning confocal microscope (LSM 510; Carl Zeiss, Inc.). 
  In the second part, 200   μ  g/ml of p31-49  –  TAMRA was added to the 
apical compartment of duodenal biopsies from patients with active CD, pa-
tients with treated CD, and control patients, placed in Ussing chambers. After 
15 min at 37  °  C, the biopsies were removed, embedded in Tissue-Tek, cryo-
sectioned, and submitted to immunofl  uorescent staining with 24   μ  g/ml of a 
goat anti-hIgA  –  FITC (colocalization peptide  –  IgA). 
  Immunogold electron microscopy 
  Biopsies were fi  xed with 2% paraformaldehyde/0.2% glutaraldehyde (Elec-
tron Microscopy Sciences) in 0.2 M of phosphate buff  er, pH 7.4. Free alde-
hyde groups were quenched with 50 mM glycine in PBS, and cells were 
embedded in 10% gelatin, infused in 2.3 M sucrose, and frozen in liquid 
  nitrogen. Ultrathin cryosections were prepared with an ultracryomicrotome 
(FCS; Leica) and double immunogold-labeled with anti-CD71 mAb (H68.4; 
Invitrogen), followed by rabbit anti  –  mouse Ig (Dako) and protein A conju-
gated to 15-nm gold particles and a goat polyclonal anti  –  human IgA anti-
body (Abcam), followed by rabbit anti  –  goat Ig (Dako) protein A conjugated 
to 10-nm gold particles. Protein A conjugated to gold particles was purchased 
from Cell Microscopy Centre. To avoid crossover of protein A binding, 
double labeling was performed sequentially, and sections were treated with 
glutaraldehyde between the two incubations to prevent blending of the dif-
ferent antibody  –  gold complexes (  60  ). 
  Synthesis and radiolabeling of gliadin peptides 
  p31-49 (19-mer, LGQQQPFPPQQPYPQPQPF; mol wt, 2221) and p56-
88 (33-mer, LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF; mol wt, 
3903) were synthesized (Covalab) and radiolabeled (tritiated) on selected 
proline residues as previously described (  15  ). The specifi  c activity of the ra-
diolabeled peptide batches used in this study was between 2 and 3 Ci/mmol. 
Radiolabeling allowed us to follow peptide degradation during intestinal 
transport, using RP-HPLC chromatography with online detection of radio-
activity. Immunofl  uorescence studies were performed with p31-49 coupled 
to 5-TAMRA (5-carboxytetramethylrhodamine) via a spacer (Ahx) at the 
N-terminal portion of the peptide (Covalab). 
  Transport of p31-49 and 33-mer across duodenal biopsies 
in Ussing chambers 
  Four to six duodenal biopsies from each patient were mounted in adapted 
Ussing chambers, exposing a surface area of 0.025 cm  2  , as previously de-
scribed (  15  ). Each biopsy was used to quantify apical to basal fl  ux of radiola-
beled p31-49 or 33-mer and to analyze tritiated peptide fragments in the basal 
compartment. p31-49 or 33-mer was placed on the apical side at 0.2 mg/ml, 
together with 1850 kBq (50   μ  Ci) of   3  H-labeled peptide. 
  All inhibitors tested, namely nonspecifi  c IgA1 (mIgA, dIgA, and pIgA 
at a fi  nal concentration of 50   μ  g/ml, respectively, prepared as described in 
Purifi  cation of IgA...), 50   μ  g/ml SIgA (Biotrend), 30   μ  g/ml of soluble IgA 
receptors (sCD71 or sCD89), 50   μ  g/ml IgG (Biotrend), 10   μ  g/ml of human 
Tf (T3309; Sigma-Aldrich), 20   μ  g/ml of anti-CD71 mAb A24 (  57  ), 30   μ  g/ml 
of anti  –  human SC mAb (SC-05; Monosan), 10  μ  g/ml of anti-Tgase II mAb 6B9 
(a gift from T. Issekutz, Dalhousie University, Halifax, Canada), and 500   μ  M 
of dansyl cadaverin, a Tgase II inhibitor (Sigma-Aldrich), were added to the 
apical compartment 30 min before adding the peptide. Finally, preliminary 
experiments indicated no nonspecifi  c binding of   3  H-labeled p31-49 to myeloma 
pIgA1, SIgA, or sCD71 (unpublished data). 
  RP-HPLC analysis 
  p31-49 or p56-88 (33-mer) and their fragments present in the apical and 
basal compartments bathing the duodenal biopsies in the Ussing chamber 
were analyzed after 3 h of incubation by radio  –  RP-HPLC, as previously 
described (  15  ). Acquisition, integration, and calculation of the percentage of 
  Measurement of IgA and IgA-containing complexes in serum 
and duodenal secretions 
  IgA immune complexes in serum samples were analyzed by precipitation 
with polyethylene glycol 6000 (PEG 6000), as previously described (  58  ). 
PEG precipitates were dissolved in 500   μ  l of 0.01 M phosphate buff  er, pH 
7.4, containing 0.5 M NaCl and 0.05% Tween 20. IgA immune complex in 
duodenal secretions was measured after precipitation with saturated ammo-
nium sulfate. Total immune complex content was estimated by measuring OD 
at 280 nm. The specifi  city of the immune complex present in serum and du-
odenal secretions and the presence of Tgase in these complexes was checked 
by ELISA. 96-well plates were coated with either 5   μ  g/ml of pepsin/trypsin 
gliadin hydrolysate or 5   μ  g/ml of rabbit polyclonal anti-Tgase antibody (US-
Biological), respectively, blocked with 5% gelatin in borate buff  er, and incu-
bated overnight at 4  °  C with serum PEG immune complex diluted 1:10 and 
1:100 in PBS containing 0.05% Tween 20 or with undiluted immune com-
plex from duodenal secretions. After washing, 1:2,000 alkaline phosphatase 
(AP)  –  anti-IgA (SouthernBiotech) was added for 2 h at 37  °  C. The reaction 
was developed by adding AP substrate, and absorbance was read at 405 nm. 
Results are expressed as OD. 
  Flow cytometry analysis of SIgA binding to CD71 
  SIgA binding was examined with an indirect immunofl  uorescence assay in 
which 0.5   ×   10  6   Daudi cells, which express CD71 as the only IgA recep-
tor (  19  ), were incubated with 10   μ  l SIgA (0.5 mg/ml; Fitzgerald) for 1 h 
on ice before washing and incubation for 20 min at 4  °  C with a biotinyl-
ated anti-IgA mAb clone (CH-EB6-8) that recognizes both IgA1 and IgA2 
(  59  ). After washes, allophycocyanin-streptavidin (SouthernBiotech) was 
used as a developing reagent. For inhibition studies, SIgA was preincubated 
with soluble CD71 receptor at 0.5 mg/ml for 1 h before adding the cells. 
Immunofl  uorescence was analyzed by fl  ow cytometry (FACSCalibur; Bec-
ton Dickinson). 
  Immunohistochemical analysis of duodenal biopsies 
  Immunoperoxidase labeling.     CD71, CD89, and SC were detected on 6-  μ  m 
cryosections of duodenal biopsies fi  xed in cold acetone for 15 min at     20  °  C 
and rehydrated with 0.1% PBS/BSA. Endogenous peroxidase and biotin 
were blocked with 3% H  2  O  2   and the Blocking Biotin system (Dako), respec-
tively, and other nonspecifi  c binding sites were blocked with horse serum. 
Sections were incubated for 60 min with 22   μ  g/ml of anti-CD71 mAb A24 
(  57  ), 10   μ  g/ml of biotinylated anti-CD89 mAb A77 (  57  ), or 10   μ  g/ml of anti-
hSC mAb (Monosan), respectively. After rinsing in 0.1% PBS/BSA, primary 
antibodies were detected with an indirect biotin/streptavidin-peroxidase label-
ing kit (ChemMate; Dako) with DAB as substrate. Sections were counterstained 
with Mayer  ’  s hematoxylin. 
  Immunofl  uorescence labeling.     Immunofl  uorescence studies comprised 
two parts: (a) a study of fresh-frozen duodenal biopsy sections and (b) a study 
of duodenal biopsy specimens incubated for 15 min at 37  °  C in Ussing chambers 
in the presence of fl  uorescent TAMRA  –  p31-49 in the apical compartment 
before freezing and cryosectioning. 
  In the fi  rst part, fresh duodenal biopsies were frozen in Tissue-Tek 
(    80  °  C; Euromedex), cut into 6-  μ  m-thick sections, and kept at     20  °  C until 
staining. Biopsy sections were thawed, fi  xed in cold acetone, and rehydrated 
in 0.1% PBS/BSA, and nonspecifi  c sites were blocked for 30 min with anti-
body diluent (ChemMate; Dako). Primary antibodies  —  24   μ  g/ml of poly-
clonal goat anti-hIgA  –  FITC (Abcam), 22   μ  g/ml of anti-CD71 (A24) mAb 
(  57  ), 50   μ  g/ml of anti  –  human cytokeratin (epithelial) mAb (USBiological), 
or 25   μ  g/ml of rabbit polyclonal antialkaline phosphatase (Abcam)  —  were 
incubated for 60  –  90 min. After rinsing, secondary antibodies to A24 (15   μ  g/ml 
of Cy5-conjugated goat anti  –  mouse IgG [H+L] antibody), anticytokeratin 
mAb (30   μ  g/ml of Texas red  –  conjugated goat anti  –  mouse IgG [H+L]), or 
antialkaline phosphatase antibody (20   μ  g/ml of Texas red  –  conjugated sheep 
polyclonal anti  –  rabbit IgG [H+L]; Abcam) were added for 30 min. Tissue 
sections were mounted with antifade mounting medium (Vectashield) and 
stored at 4  °  C until analysis. JEM VOL. 205, January 21, 2008 
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radioactivity eluted in each peak were performed with Radiostar software 
(Berthold). In this setting, free   3  H-labeled proline (the radiolabeled amino 
acid in the peptide sequence) is eluted with a retention time (Rt) of 4 min, 
whereas intact p31-49 and 33-mer are eluted at 24.5 and 30 min, respectively. 
As already reported (  15  ), there was no degradation of p31-49 or 33-mer in 
the apical compartment after 3 h of incubation. Radio  –  RP-HPLC analysis 
of the basal compartments allowed us to evaluate p31-49 and 33-mer degra-
dation during their intestinal transport by calculating the relative percentage 
of intact peptides and their degradation fragments. Our previous mass spectrom-
etry studies (  16  ) showed that p31-49 fragments eluting between 17 and 21 min 
(named   “  active fragments  ”  ) correspond mainly to p31-43, a toxic sequence of 
p31-49 (  11  ), and that large 33-mer fragments eluting between 23 and 28 min 
correspond to immunostimulant 12-mer peptides (named   “  large fragments  ”  ). 
  Statistical analyses 
  The results are reported as means   ±   SD or as scatter plots and medians. Multiple 
comparisons (analysis of variance) followed by group-to-group comparisons 
were performed with the general linear model procedure or the nonpara-
metric Wilcoxon test of the SAS software package (SAS Institute). Diff  er-
ences were considered to be statistically signifi  cant at P   <   0.05. 
  Online supplemental material 
  Fig. S1 examines IgA expression in crypt and surface epithelium of control 
subjects and active celiac patients. Fig. S2 presents an immunogold elec-
tron microscopy study of IgA and CD71 expression or colocalization in 
duodenal biopsies from one control subject and two patients with active 
CD. Fig. S3 describes the attempted inhibition of intact   3  H-labeled p31-49 
transport in active celiac patients in the presence of anti-CD71 mAb, anti-
SC mAb, anti-Tgase II mAb, or the Tgase inhibitor dansyl cadaverin. On-
line supplemental material is available at http://www.jem.org/cgi/content/
full/jem.20071204/DC1. 
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